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Systemic PPARc Ligation Inhibits Allergic Immune
Response in the Skin
Anja Dahten1, Christin Koch1, Dennis Ernst1, Corinna Schno¨ller2, Susanne Hartmann2 and Margitta Worm1
We have shown previously that specific ligands of the peroxisome proliferator-activated receptor-g (PPARg)
inhibit the systemic allergic immune response. The objective of this study was to investigate the impact of
PPARg-ligand treatment on the local allergic immune response. We established a murine model exhibiting
clinical and histological features of AD-like skin lesions with high reproducibility. In this model, the PPARg
ligand was applied in an either preventive or therapeutic manner via systemic and local routes. The affected skin
areas were assessed by standardized skin score, histological analyses, and immunohistochemical examinations.
Our data show that systemic application of PPARg ligand by a preventive protocol led to significantly reduced
onset of eczematous skin lesions. This was confirmed by histology, showing decreased skin thickness
accompanied by significantly reduced infiltrations of CD4þ and CD8þ lymphocytes but also mast cells.
Additionally, early allergen-specific IgE and IgG1 responses were reduced (day 21/35), whereas IgG2a levels
remained unchanged. In conclusion, our results demonstrate that PPARg-ligand treatment inhibits not only
systemic allergic immune response, but also local allergen-mediated dermatitis. Our findings point to
therapeutic strategies, including a PPARg-ligand-based treatment.
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INTRODUCTION
The peroxisome proliferator-activated receptor-g (PPARg)
belongs to the nuclear receptor class II superfamily, showing
pleiotropic effects in inflammatory processes in their capacity
as ligand-dependent transcription factor (Zingarelli and Cook,
2005). PPARg was found to be expressed in different cell
types, involving B and T lymphocytes (Greene et al., 2000),
monocytes/macrophages (Tontonoz et al., 1998), dendritic
cells (Nencioni et al., 2002), but also in epidermal differen-
tiating keratinocytes (Rivier et al., 1998). Although many
nuclear receptor class II members, like the retinoid-acid-
(Vollberg et al., 1992), vitamin D receptor (Xie et al., 2002;
Bikle et al., 2003), as well as PPARa and PPARd (Tan et al.,
2001; Schmuth et al., 2004), are known to be involved in skin
homeostasis, less is known about the impact of PPARg.
Current studies indicate that activation of PPARg can improve
hyperproliferative skin diseases through specific agonists,
belonging to the group of thiazolidinediones (Ellis et al.,
2000; Demerjian et al., 2006). We have shown previously
that the thiazolidinedione ciglitazone inhibits systemic
allergic immune response by inhibiting IgE production, but
also (pro)inflammatory cytokines of the T-cell-dependent
immune response in vitro and in vivo (Ruhl et al., 2003).
Furthermore, a recent analysis of atopic dermatitis (AD)
skin lesions show increased PPARg expression not only in
keratinocytes, but also in infiltrating T cells and monocytes
(Dahten et al., 2007). In murine asthma models, ciglitazone
reduced allergic airway hyperresponsiveness and charac-
teristic parameters of T-helper cell-2 (Th2)-driven airway
inflammation, like GATA-3, IL-4, IL-13 (Mueller et al., 2003;
Trifilieff et al., 2003; Woerly et al., 2003), suggesting that
systemic and local effects mediated by PPARg ligation.
Whether PPARg ligation affects local Th-driven inflammation
in the skin besides its systemic immune modulation remains
unknown.
AD is a chronic remittent skin disease, which may be
associated with IgE-dependent diseases like allergic asthma,
food allergy, and allergic rhinitis (Leung and Bieber, 2003;
Spergel and Paller, 2003). Interactions between the local and
systemic immune responses orchestrated by resident and
infiltrating cells play a crucial role in the manifestation of
AD. In mice, allergen-mediated dermatitis was initially
demonstrated by epicutaneous (e.c.) application of proteins
(Wang et al., 1996, 2007; Spergel et al., 1998). In these
models, the sensitized skin areas exhibit significant histo-
logical signs such as skin thickening and increased mono-
nuclear infiltrates, which are accompanied by elevated
allergen-specific IgE and IgG. However, until now, data on
reproducibility and demonstration of the clinical outcome
were missing in these mouse models.
In this study, we investigated the severity of eczematous
skin lesions after preventive and therapeutic PPARg-ligand
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treatment in a murine allergic dermatitis model. We demons-
trate that repeated systemic application of the PPARg ligand
results in a decrease of clinical features of allergic dermatitis,
like erythema, edema, and oozing, after allergen exposure.
These observations were confirmed by histological examina-
tions showing reduced epidermal and dermal hyperplasia,
accompanied by significantly reduced infiltrations of CD4þ
and CD8þ lymphocytes and mast cells in sensitized skin
areas of PPARg-ligand-treated mice. The analysis of allergen-
specific humoral immunity points to a PPARg-mediated
inhibition of allergen-specific IgE and IgG1 responses during
sensitization.
RESULTS
Repeated systemic and local sensitizations with OVA induced
reproducible skin inflammation
To establish a murine model showing local skin inflammation
with high response rates, we initiated a panel of different
sensitization protocols (Figure 1), following the previous
protocol of e.c. ovalbumin (OVA) sensitization (Spergel et al.,
1998; Wang et al., 2007). Our data show that only e.c. OVA
sensitization, in combination with an initial systemic
sensitization, lead to significant response rate with visible
AD-like skin lesions in comparison with age- and weight-
matched mice without any OVA sensitization. As shown in
Figure 2a, these sensitized mice (OVA) developed local
dermatitis with visible clinical symptoms, like dryness,
extension, erythema, edema, papules, oozing, and/or crusts,
which were similar to resemble clinical skin features of
human AD. The observed clinical symptoms were graded by
the total clinical skin score (CSS) up to 13 points (with a mean
of 9±1), whereas non-sensitized mice reached a mean of
4±1. Furthermore, affected skin areas showed histopatho-
logical features of eczema, such as epidermal and dermal
skin thickening (twofold), parakeratosis, spongiosis, and a
dense perivascular infiltrate (Figure 2b), which was accom-
panied by increased mast cell infiltration and degranulation
(Figure 2c). Immunohistochemical analysis revealed signi-
ficant dermal increase up to sixfold of dermal CD4þ
(Figure 2d), threefold of CD8þ (Figure 2e), and twofold of
CD11þ cells (Figure 2f). The cytokine profile in local skin
lesions was dominated by Th2 cytokines, like IL-4 and IL-10,
as determined by PCR analysis (Table 1).
Skin characteristics of mice with systemic and local sensi-
tization (model III) in comparison with mice, which were
sensitized only by e.c. allergen application (model II) indicate
that the combined sensitization model led more to formation
of AD-like skin lesions (Table 1). First, the clinical signs
and symptoms of AD, graded by the CSS, were strong, clear
visible (Figure 2a), and exhibited high response rates
(Po0.01) only in mice sensitized by the intraperitoneal
(i.p.)/e.c. method, whereas e.c. sensitization alone did not
induce significant reproducible skin features. Accordingly,
histological changes regarding skin thickness and numbers
of infiltrating CD4þ lymphocytes and mast cells were less
prominent in model II.
Next, we used this dermatitis model to study the effect
of PPARg-ligand treatment on the local inflammatory
immune response in eczematous skin lesions. Therefore,
severity of inflammatory skin lesions was analyzed in mice
after repeated PPARg-ligand applications at three different
time points of (Figure 1).
Repeated exposure of PPARc-ligand improved severity of
clinical AD symptoms in the skin
Macroscopic examination of dermatitis severity (Figure 3)
shows that OVA-sensitized mice reached a mean CSS of 9±1
points. The non-sensitized mice group developed due to the
patched application also a slight inflammatory response,
which was significantly lower than in the OVA group (CSS
of 4±1). The PPARg-ligand application groups show that the
group with i.p. exposures of ciglitazone clearly exhibited less
inflammation of lesional skin, regarding erythema, oozing,
and crusts. By contrast, local application of ciglitazone did
not alter the clinical outcome of AD-like skin lesions at all.
Systemic PPARc-ligand treatment results in decreased skin
inflammation
The amelioration of skin inflammation by systemic PPARg
ligation was also reflected by reduced skin thickness and less
perivascular infiltrates. Figure 4a shows reduced epidermal
and dermal thickness of mice skin, which received systemic
PPARg-ligand treatment. This was accompanied by less
infiltration of lymphocytes into the skin (Figure 4b). Detailed
analysis of systemically treated mice groups revealed that
preventive treatment with PPARg ligand was more efficient
than therapeutic PPARg-ligand application. First, epidermal
thickening was less prominent, and second, less infiltration
of epidermal and dermal lymphocytes, but also mast cells,
was observed. However, neither preventive nor therapeutic
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Figure 1. Protocol of OVA sensitization and PPARc-ligand treatment in
mice. Mice were sensitized intraperitoneally with 10 mg OVA on days 1, 14,
and 21 (black arrows), and epicutaneously by patches with 100 mg OVA,
twice a week (gray arrows). E.c. sensitization comprised three 1-week
exposures. (a) Preventive treatment with PPARg-ligand started 2 days before
the first sensitization and ended with day 35. (b) Therapeutic exposure
with PPARg-ligand occurred from day 35 until 69. In both application groups,
the ligand was applied at 4mg kg1 body weight via i.p. injection, every
second day. (c) PPARg ligand was applied epicutaneously in combination
with OVA sensitization via patch. On day 70 mice were killed and skin
and blood samples were collected.
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PPARg-ligand treatment ameliorated the numbers of CD11þ
cells (data not shown).
Preventive PPARc ligation inhibits allergen-specific IgE immune
response
As patients with AD often exhibit elevated specific IgE levels
(Novak and Bieber, 2003), we examined specific IgE in the
different treatment groups (Figure 5a). After OVA sensitiza-
tion (black bars), specific IgE, IgG1, and IgG2a levels
increased dramatically. Preventive application of PPARg-
ligand (Figure 1a) resulted in a profound decrease of specific
IgG1 on day 21 (white bars). A significant inhibition of
specific IgG1 was also detectable on day 35. Specific IgE
level peaked later than IgG1 level, and was also significantly
reduced on day 35 in the group receiving preventive PPARg-
ligand treatment. Therapeutic treatment with PPARg ligand
(Figure 1b) did not bring about a significant change in the
humoral immune response (data not shown). Importantly,
allergen-specific IgG2a production was not reduced by
PPARg-ligand treatment, ruling out general immunosuppres-
sion by ciglitazone at the used concentrations. These data
point to PPARg-mediated suppression of the development, but
not inhibition, of an established humoral immune response.
To find out whether alteration of humoral immune
response is T-cell cytokine dependent, we next examined
IL-4/IFN-g production (Figure 5b). The observation of ex vivo
measurements in cultured splenocytes showed no detectable
baseline cytokine production, which increased after stimula-
tion with OVA and anti-CD28 up to 750±95 pgml1 (IL-4)
and 130±40 pgml1 (IFN-g), respectively. Splenocytes from
mice receiving therapeutic PPARg-ligand treatment exhibited
reduced IL-4 (60±10%) and IFN-g (85±10%) responses.
In mice receiving preventive PPARg-ligand treatment, a
decrease in IFN-g production was clearly detectable.
DISCUSSION
Our recent findings point to the role of PPARg ligands in
the regulation of systemic inflammatory immune responses
(Ruhl et al., 2003; Dahten et al., 2007). Now we demonstrate
the impact of systemic PPARg ligation on local inflammatory
immune response in the skin.
We developed an optimized murine AD model showing
local inflammatory skin lesions that were clinically, histo-
logically, and immunologically comparable to human AD. In
contrast to previously described models, our protocol leads to
induction of AD-like eczema with macroscopic skin features
and high response rates. It has been shown that CD4þ
T cells predominate in the dermis of acute skin lesions of AD
patients, whereas only a few CD8þ T cells were detected
(Simon et al., 2004). This is consistent with our data showing
PBS OVA PBS OVA
Figure 2. Histological analysis of skin biopsies from OVA-sensitized mice (right column) compared with non-sensitized mice (left column). Sensitized
mice show (a) clinical skin features, like erythema, edema/papule, oozing, and dryness within the patched areas (encircled). (b) Hematoxylin- and (c) o-toluidine
blue staining of 5-mm sections revealed thickness of epidermis and dermis, accompanied by a dense dermal mononuclear infiltrate consisting of
mononuclear and mast cells. Immunohistochemical staining of 4-mm sections pointed to significantly increased numbers of CD4þ (d), CD8þ (e),
and CD11cþ (f) cells after repeated OVA exposures. Images in panels (b) and (c) were taken at original magnification  100 (bar¼ 200mm) and that in
panels (d)–(f) at original magnification 200 (bar¼ 100 mm).
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strong CD4þ T-cell infiltration in the skin. However, our data
also show that this sensitization protocol recruits significant
amounts of CD8þ cells as well. Recently, some studies
pointed to the role of epidermal CD8þ cells in the patho-
genesis of AD (Akdis et al., 1999; Savinko et al., 2005). In
mice depleted of CD8þ , no significant signs of inflammation
could be observed after allergen exposure, whereas CD4þ
depletion did not abolished allergen-induced skin inflamma-
tion (Hennino et al., 2007). These data suggest CD8þ T cells
are important effector cells for allergen-induced skin inflam-
mation. Whether these cells are allergen-specific or are a
result of bystander activation is currently under investigation.
Since PPARg was shown the be expressed in CD8þ
lymphocytes (Dahten et al., 2007), this cell population may
be involved in PPARg-targeted treatment of AD.
The local skin lesions were also characterized by sparse
epidermal infiltration of dendritic cells and increased expres-
sion of Th2 cytokine profile (IL-4, IL-10). These observations
are in line with reports on acute skin lesions (Allam and
Novak, 2006; Boguniewicz et al., 2006). From this finding,
we determined an induction of allergen-specific humoral
response in sensitized mice. Elevated total and specific IgE
levels, but increased expression of cytokines, like IL-4, and
IL-10, have also been reported previously in the majority of
AD patients (Ohmen et al., 1995; Leung and Bieber, 2003;
Novak and Bieber, 2003) and also in murine AD models
(Nelde et al., 2001; Chen et al., 2004; Gutermuth et al.,
2004; Lewkowich et al., 2004).
These data underline the importance of route and duration
of allergen exposure regarding development and outcome
of allergen-induced dermatitis. Our AD model provides
an optimized tool to study the pathogenic processes of AD
and to establish treatment approaches under well-defined
conditions.
PPARg has been shown to exhibit anti-inflammatory
activities in different models of inflammatory diseases, such
as atherosclerosis, inflammatory bowel disease, or multiple
sclerosis (Forman et al., 1995; Su et al., 1999; Natarajan
et al., 2003). Our own previous studies indicated that the
PPARg-ligand ciglitazone inhibits allergic immune response
by inhibiting Th2-driven IgE production and also production
of (pro)inflammatory cytokines of the Th response in vitro and
in vivo (Ruhl et al., 2003). We now show that ciglitazone
inhibits not only systemic but also local inflammatory
immune response in the skin by diminishing the severity
of allergen-induced dermatitis. Our data demonstrate that
systemic, but not topical, applications of PPARg-ligand
reduce the inflammatory response in the skin. Several lines
of evidence support this finding. First, only mice obtaining i.p.
Table 1. Systemic OVA sensitization followed by
repeated e.c. OVA exposure-induced skin
inflammation and exacerbates allergic dermatitis
Route of sensitization
I II III
Analysis
W/o
OVA
OVA
e.c.
OVA
e.c.+i.p.
Eczema versus non-eczema 0/10 5/10 9/10
Clinical skin score1 4±1 6±1a 9±1a,b**
Skin thickness (mm)2
Epidermis 14±1 19±1a** 23±1a***b**
Dermis 73±4 73±4 142±4a,b***
Cell infiltrates (per HPF)3
Mast cells 24±2 24±2 33±2a,b**
CD4 7±1 22±3a** 46±3a,b***
CD8 4±1 5±1 14±2a***
CD11c 7±1 ND 18±2a**
Cytokine expression4
IL-4 1 2±1* 10±2**
IL-10 1 1±1 2±1
IFN-g 1 4±1 1±1
e.c., epicutaneous; HPF, high-power field; i.p., intraperitoneal; ND, not
detected; OVA, ovalbumin; PBS, phosphate-buffered saline.
Data are shown as mean±SEM (n=10). Statistical significance (P) is based
on Mann–Whitney U-test, ***Po0.001, **Po0.01, and *Po0.05, versus I
(a), versus II (b).
1Clinical skin score was defined as the sum of individual scores grades as
0 (none), 1 (mild), 2 (moderate), and 3 (severe) for erythema, edema/
papule, oozing/crusts, dryness, and extension.
2Skin thickness was determined in 5-mm hematoxylin-stained skin sites by
digital measurement tools.
3Positively stained cells were counted in 10 HPFs and expressed as cells
per HPF.
4Expression of cytokine mRNAwas determined by reverse transcriptase-PCR.
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Figure 3. Improved severity of dermatitis in PPARc-ligand-treated mice.
In non-sensitized, vehicle-treated mice (white bar), OVA-sensitized mice
(black bar), and OVA-sensitized plus PPARg-ligand (PPARg-l.)-treated
mice (gray bars), clinical skin conditions (erythema, edema/papule, oozing/
crusts, dryness, and extension) were macroscopically scored at the
sensitized belly area and grades as 0 (none), 1 (mild), 2 (moderate), and
3 (severe). The total clinical skin score for each mouse was defined as
the sum of individual scores for every described sign and symptom. Data
are presented as mean values±SEM (bars). Statistical significance (P) is
based on Mann–Whitney U-test; NS indicates no statistical significance.
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treatment developed less clinical signs of protein dermatitis,
like erythema, oozing, and crusts. Second, histological signs
of dermatitis, like skin thickness and numbers of dermal
CD4þ lymphocytes, were significantly reduced. However,
we cannot rule out the possibility that inefficient local
penetration of PPARg ligand was responsible for the missing
efficacy. Venkatraman et al. (2004) have shown anti-inflam-
matory effects for orally and also topically applied thiazoli-
dinedione derivatives in an oxazolone-challenged dermatitis
model. In line with our results, oral application of PPARg
ligands acts at lower dosages than topical applications, which
indicates improved systemic mechanisms for these sub-
stances. The fact that therapeutic application of systemic
PPARg-ligand treatment seems to be less efficient than its
preventive application, points in turn to the less important role
of PPARg in the established allergic immune response. Our
histological data confirm this assumption. Only by preventive
PPARg-ligand application could skin thickening and numbers
of CD8þ lymphocytes and mast cells be significantly
reduced, reaching the numbers in non-sensitized mice.
IgE production is a prerequisite for type-1 allergic diseases
(Geha et al., 2003). In line with our previous data, analysis of
the humoral immune response shows ameliorated allergen-
specific IgE and IgG1 production in PPARg-ligand-treated
mice (Ruhl et al., 2003). In preventively PPARg-treated mice,
showing significantly reduced dermatitis, specific IgG1 and
IgE levels also were significantly reduced. It has been shown
that severity of AD correlates with elevated levels of IgE
(Flohr et al., 2004; Boguniewicz et al., 2006). If so, it remains
to be determined whether non-IgE-mediated (intrinsic) form
of AD will be affected by PPARg-ligand treatment as well.
Patients with extrinsic AD, besides elevated IgE levels, exhibit
increased Th2 immune response. Also in mice, IgE and IgG1
responses are Th2 cell dependent (Coffman, 1993). Although
IL-4 production was decreased in the therapeutic protocol,
humoral immune response was not. Hahn et al. (2003)
demonstrated previously that antagonizing the IL-4 receptor
during the OVA sensitization phase leads to inhibition of
OVA-specific IgE induction and development of allergic
phenotype. By contrast, inhibition of IL-4 did not affect the
ongoing IgE response after sensitization. Since depletion of
IFN-g results in less allergen-induced dermal hypertrophy
(Spergel et al., 1999), reduced IFN-g production in spleno-
cytes from preventively and therapeutically treated mice
points to a possible mechanism for the significantly reduced
dermal thickness in both treatment groups.
Taken together, our data suggest that PPARg-ligand-
mediated amelioration of allergic symptoms in the skin were
mediated by a modulation of the humoral and also the
cellular immune response. PPAR ligands repress the secretion
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Figure 4. Histological features of dermatitis were reduced in mice with repeated systemic PPARc-ligand treatment. Skin thickness (a) and cell infiltrates
of CD4þ , CD8þ , and mast cells (b) were determined in 4–5 mm sections of frozen skin from non-sensitized, vehicle-treated mice (white bar),
OVA-sensitized mice (black bar), and OVA-sensitized plus systemically (preventive, therapeutic) PPARg-ligand (PPARg-l.)-treated mice (gray bars).
Skin thickness (mm) was determined in hematoxylin-stained skin site by digital measurement tools. Cells positive for the immunohistochemical stain
were counted in 10 high-power fields and expressed as cells per high-power field. Data are presented as mean values±SEM (bars). Statistical significance
(P) is based on Mann–Whitney U-test; NS indicates no statistical significance.
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of chemokines by epithelial and other cells, decreasing
recruitment of leukocytes to the site of inflammation (Straus
and Glass, 2007). As shown in an asthma model, PPARg
ligands reduce the chemokine-mediated infiltration of inflam-
matory cells (Nie et al., 2005). The anti-inflammatory activity
of PPARg ligands in mouse models, and our finding that
PPARg ligand exerts anti-inflammatory effects on the devel-
opment of allergic skin inflammation, suggests a possible
application in treating allergic diseases, including AD.
Therefore, our data may provide the basis for development
of therapeutically molecules involving a PPARg-targeted
immune modulation.
MATERIALS AND METHODS
Mice sensitization and treatment
Eight-week-old female BALB/c mice were purchased from the
Federal Institute of Risk Assessment, Berlin. All mice were housed
within an accredited animal facility at the Charite´-Universita¨tsme-
dizin (Berlin), and maintained under pathogen-free conditions with
standard laboratory food and water ad libitum. Procedures were
performed in compliance with protocols approved by the local State
Office of Health and Social Affairs.
As shown in Figure 1, mice were sensitized intraperitoneally
on days 1, 14, and 21 with 100 ml of 10 mg OVA adsorbed to
10 mg Al(OH)3 or with phosphate-buffered saline as control (all
Sigma-Aldrich, Taufkirchen, Germany). E.c. allergen application was
performed as described previously (Spergel et al., 1998). Briefly,
after i.p. anesthesia with 0.02% xylazin solution (Bayer, Leverkusen,
Germany), the skin on the mice belly was shaved and OVA or
phosphate-buffered saline was applied by the patch test method.
Each mouse had a total of three 1-week exposures to the same skin
site. Ciglitazone (Alexis Biochemicals, Gru¨nberg, Germany) was
dissolved at 25mgml1 in DMSO and further diluted in phosphate-
buffered saline before application. Ciglitazone or vehicle (control)
was applied either preventively (Figure 1a) or therapeutically
(Figure 1b) via i.p. injection at 4mg kg1 body weight every second
day, or by e.c. application at 10mM by the allergen-patch
application method (Figure 1c). Preventive treatment with PPARg
ligand was started 2 days before the first sensitization and was
stopped at day 35. Therapeutic application with PPARg ligand was
**
*
*
**
****
OVA-IgG1 OVA-IgE
100,000,000
10,000,000
1,000,000
LU
/m
l lo
g
Day 0 Day 21 Day 35
OVA-IgG2a
Day 70
Day 0 Day 21 Day 35 Day 70
Day 0 Day 21 Day 35 Day 70
100,000
10,000
1,000
OVA
OVA + PPARγ-I. preventive
OVA
OVA + PPARγ-I. preventive
OVA + PPARγ-I. therapeutic
100,000
10,000
1,000
100
10
1
120
100
80
60
40
20
0
IL
-4
 p
ro
du
ct
io
n 
in
 %
OVA
PPARγ-I.
–
– –
+ +
+
+
+
–
– –
+ +
+
+
+
120
100
80
60
40
20
0
IF
N
γ p
ro
du
ct
io
n 
in
 %
Figure 5. The systemic immune response is regulated by systemic PPARc ligation. (a) OVA-specific IgG1, IgE, and IgG2a levels were analyzed in the sera
of OVA-sensitized (black bar) and OVA-sensitized plus preventively PPARg-ligand (PPARg-l.)-treated mice (white bar) by ELISA. Time points of analysis
were days 21 (during systemic sensitization), 35 (after systemic sensitization), and 70 (after e.c. sensitization). At day 0 (before systemic sensitization) no
specific Ig levels were detectable. (b) IL-4 and IFNg production were analyzed in the supernatants of unstimulated and OVA plus anti-CD28-restimulated
splenocytes of OVA-sensitized mice (black bar), OVA-sensitized plus preventively PPARg-ligand-treated mice (white bar), and OVA-sensitized plus
therapeutically PPARg-ligand-treated mice (gray bar) by ELISA. The asterisks indicate statistical significance (P), based on Mann–Whitney U-test comparing
OVA-sensitized mice with mice sensitized plus ligand treated; **Po0.01 and *Po0.05.
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performed from day 35 until 69. At day 70 mice were killed and skin,
spleen, and blood samples were collected for further analysis.
Clinical skin features
To evaluate the severity of OVA-induced eczematous skin lesions,
we used a skin scoring system, which considers typical skin features
of AD, like erythema, edema/papules, oozing/crusts, dryness, and
extension. The standardized clinical skin score (CSS) is based on the
clinical features of human AD (Hanifin and Rajka, 1980; Leung
et al., 1990) and was previously described in a murine model with
spontaneous manifestation of AD-like skin lesions (Matsuda et al.,
1997). For calculating total CSS, the marked lesions, visible on the
patched mice area, were graded as 0 (none), 1 (mild), 2 (moderate),
and 3 (severe) by two independent persons. The total score was
taken as index of dermatitis severity.
Histological analysis
For histological analysis, 5-mm sections of skin samples were stained
with hematoxylin for 1minute. Thickness of epidermis and dermis
was determined by Axiovision measuring-tools on the Axioplan light
microscope (Zeiss, Berlin, Germany) at  100 magnification. Ten
measurements were obtained for each mouse and expressed in
micrometers with mean and SEM calculated.
Immunohistochemistry
Sections measuring 4mm were prepared and used for staining by the
streptavidin–biotin complex method. Sections were incubated with
rat anti-mouse CD4 (RM4-5) and CD8 (53-6.7), followed by
incubation with biotinylated goat anti-rat IgG (all BD Pharmingen,
Heidelberg, Germany). CD11c-positive cells were detected using
purified hamster anti-mouse antibody (HL3) and biotinylated anti-
hamster IgG cocktail (BD Pharmingen). Signals were detected by
Chem-Mates alkaline phosphatase/red detection kit (Dako,
Hamburg, Germany) and by hematoxylin counterstaining. To detect
infiltrating mast cells, 5-mm skin sections were stained for 1 hour
with o-toluidine blue. Positively stained cells were counted in
10 high-power fields at  200 magnification and expressed as cells
per high-power field, with mean and SEM calculated.
RNA preparation and reverse transcriptase-PCR
Total RNA was extracted from 30 mg of frozen skin samples using
RNeasy mini Kit (Qiagen, Hilden, Germany). A 1–2mg weight of total
RNA was transcribed into cDNA using TaqMans reverse transcrip-
tion reagents according to the manufacturer’s guidelines. The mRNA
expressions of cytokines were determined using TaqMan reagents
IL-4 (Mm00445259_m1), IL-10 (Mm00439616_m1), and IFN-g
(Mm00801778_m1) primer and probe. The thermal cycling condi-
tions were set to 95 1C for 10minute, followed by 40 cycles of
amplification at 95 1C for 15 s and 60 1C for 1minute for each cycle.
Efficiency-corrected relative quantification was performed by the
2DDCT method (Livak and Schmittgen, 2001).
Serum antibody levels
OVA-specific IgE, IgG1, and IgG2a levels were measured by ELISA.
Briefly, 96-well microtiter plates were coated overnight, at 4 1C, with
100ml of 0.1 M NaHCO3 containing the appropriate antibody. Serum
samples and standards were diluted in 1% skimmed milk and
incubated for 2 hours. The amounts of bound antibody were
detected with biotin-conjugated anti-mouse isotype-specific anti-
body, followed by treatment with streptavidin–horseradish peroxi-
dase (R&D Systems, Wiesbaden, Germany) and with the peroxidase
substrate 3,30,5,50-tetra-methyl-benzidine dihydrochloride (Sigma-
Aldrich) at 405 nm. Serum titers were expressed as laboratory units
of serum dilution. Plates were read at 450 nm.
Cytokine determination
A total of 106 freshly isolated murine splenocytes were cultured
with and without 250 mgml1 OVA and 5 mgml1 anti-CD28
(both BD Pharmingen) in RPMI 1640 culture medium supplemented
with L-glutamine (2mM), penicillin (100Uml1), streptomycin
(100mgml1), and 10% heat-inactivated fetal calf serum for
96 hours (all Biochrom/Seromed, Berlin, Germany). All cell cultures
were carried out at 37 1C in a 5% CO2 atmosphere. Cytokines were
quantified in the supernatants of cultured cells by ELISA (R&D
Systems), according to the manufacturer’s guidelines.
Statistical analysis
Data were compared by non-parametric analysis (SPSS Software,
Munich, Germany) using Mann–Whitney U-test for independent
groups. P-values less than 0.05 were considered statistically
significant.
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